BDBM305344 US10144734, Example 360::US10172845, Example 360::US10441581, Example 360::US10881652, Example 360::US11648243, Example 360

SMILES CCOc1cc(-c2ccc(nc2)N2C[C@@H](N)[C@@H](C2)Oc2ccc(Cl)nn2)c2c(cnn2c1)C#N

InChI Key InChIKey=YBZZSGMHCOBKSY-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 305344   

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 88.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 88.9nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 88.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 88.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 88.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 833nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 833nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 833nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 833nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305344(US11648243, Example 360 | US10144734, Example 360 ...)
Affinity DataIC50: 833nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent